You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 43 No. 11, November 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL CONTRIBUTIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Reserpine on Regional Cerebral Glucose Metabolism jjss in Control and Migraine Subjects

Howard Sachs, MD, PhD; Alfred Wolf, PhD; Jerome A. G. Russell, PhD; David R. Christman, DSc

Arch Neurol. 1986;43(11):1117-1123.


Abstract



• The regional cerebral metabolic rate of glucose metabolism (RCMRGIu) in five headache and six control subjects was measured with positron emission tomography (PET) using the tracer 2-deoxy-D-[1-11C] glucose before and after the administration of reserpine. The short half-life of the carbon 11 tracer made possible a test-retest paradigm wherein each subject served as his own control in assessing the effect of reserpine on RCMRGIu. Thus, measurements were first performed with subjects at rest and subsequently at 1 1/2 hours after the parenteral administration of reserpine (rest-reserpine). In control subjects without history of migraine, reserpine did not induce headache, and, furthermore, PET measurements 11/2 hours after drug administration consistently showed a global increase in RCMRGIu over resting values similar to that observed in a normal control (rest-rest) group not receiving reserpine. By contrast, four of the five subjects with migraine began to experience a mild unilateral headache or visual disturbances 11/2 hours after reserpine, at which time PET scanning showed a 5% to 30% decline in RCMRGlu below the values that had been measured before reserpine injection, all well outside of the 99% confidence limits of normal variation separately determined on 25 control subjects (rest-rest). There was no apparent laterality, and subjects with a history of either common or classic migraine responded in a similar manner. The difference in percent change in RCMRGIu following administration of reserpine observed in these four subjects with migraine headaches was significantly different over all regions of interest as compared with all six control subjects receiving the drug. In one subject with migraine headaches, RCMRGIu was determined through the headache phase (31/2 hours after administration of reserpine); RCMRGIu at this time was greater than the values measured at 11/2 hours after the administration of reserpine, but still well below the resting levels. From this study, it would appear that cerebral glucose hypometabolism is an initial and persistent event in the migrainous headache induced by reserpine in susceptible subjects. Although this result supports the model of deranged cerebral function as being part of the migraine headache, it does not rule out the involvement of other or additional mechanisms in the spontaneous attack.



Author Affiliations



From the Department of Chemistry, Brookhaven National Laboratory, Upton, NY (Drs Sachs, Wolf, Russell, and Christman), the Department of Neurology, State University at Stony Brook (NY) (Dr Sachs), and Northport (NY) Veterans Administration Medical Center (Dr Sachs).


Footnotes



Accepted for publication July 10, 1986.

Presented at the Second International Headache Congress, Copenhagen, June 21, 1985, and at the 26th annual Scientific Meeting of the American Association for the Study of Headache, San Francisco, June 22, 1984.

Reprint requests to the Department of Chemistry, Brookhaven National Laboratory, Upton, NY 11973 (Dr Sachs).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Visual Field Losses in Subjects with Migraine Headaches
McKendrick et al.
IOVS 2000;41:1239-1247.
ABSTRACT | FULL TEXT  

Regional Cerebral Blood Flow and Oxygen Metabolism during Migraine with and Without Aura
Andersson et al.
Cephalalgia 1997;17:570-579.
ABSTRACT  

The Neuroendocrine Challenge Paradigm in Headache Research
Gordon et al.
Cephalalgia 1995;15:292-296.
ABSTRACT  

Is Positron Emission Tomography a Useful Tool for Studying Migraine?
Sadzot et al.
Cephalalgia 1995;15:316-322.
ABSTRACT  

The Neuroendocrine Challenge Paradigm in Headache Research
Gordon et al.
Cephalalgia 1995;15:292-296.
ABSTRACT  

Is Positron Emission Tomography a Useful Tool for Studying Migraine?
Sadzot et al.
Cephalalgia 1995;15:316-322.
ABSTRACT  

Alteration of Regional Cerebral Glucose Metabolic Rate in Non-Korsakoff Chronic Alcoholism
Sachs et al.
Arch Neurol 1987;44:1242-1251.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.